Home » Supplier Glass Vial Defects Prompt Health Canada Warning on Hospira Cancer Drug
Supplier Glass Vial Defects Prompt Health Canada Warning on Hospira Cancer Drug
Hospira is looking into a supplier glass defect following consumer complaints and a Health Canada warning to physicians not to use three lots of its cancer treatment paclitaxel injection, 300 mg/50 mL. Complaints to the company from outside Canada described particles embedded in the glass vial, rust-like marks on the vial and particles in the solution, the agency said. Hospira to date has not received any adverse event complaints for the lots.
Drug Industry Daily
Drug Industry Daily
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May